Home
Profile
Manufacturing
Quality Control
Products
  Contact Us Careers Sitemap          
   
 
:: Research & Development
:: International Collaboration
:: Business Opportunities
:: Latest Events
:: Divisions At a Glance

  press_release_btn_otherspg :: Press Releases vline_separator

  :: In Licensing   inlicensing_btn__otherspg vline_separator

  outlicensing_btn_otherspg :: Out Licensing vline_separator

 
  Mitomycin for Injection USP 2 mg
  Indications :
 

Gastro-intestinal Cancer (esophageal carcinoma)

Breast cancer

Superficial bladder tumours

Adenocarcinoma of stomach or pancreas

Non-small cell lung cancer

Head and neck squamous cell cancer

Colorectal cancer

   
  Dosage :
 
AS SINGLE THERAPY : 12 - 14 mg/m² once a month or every 35 days by intravenous infusion.
The crystals are dissolved in 200 mL of a 5% glucose solution which is then administered over a period of 30 minutes, preferably with Vitamin B Compound.

AS COMBINATION THERAPY : 10 mg/m² every 6 - 9 weeks. Higher doses have also been given.
Mitomycin-C is usually administered along with other agents (e.g. FOAM –5 FU plus vincristine plus doxorubicin plus mitomycin; SMF –streptozotocin plus mitomycin plus 5 FU; AM – doxorubicin plus mitomycin; FAM –5 FU plus doxorubicin plus mitomycin).

Dosage Adjustment :

Renal Impairment : Required.

Hepatic Impairment : Not necessary but administer with caution.
   
  Packing : 10 Vials of 2 mg
 



  Home | Careers | Site map | Contact Us



 
  All contents copyright © United Biotech (P) Limited, All rights reserved.